Idiopathic ventricular tachycardia (VT) is a cardiac arrhythmia that is seen in individuals without structural heart disease. Depending on the ECG characteristics, it can be classified as monomorphic VT or polymorphic VT, the latter comprising a number of uncommon, often malignant familial disorders, including catecholaminergic polymorphic VT (CPVT [MIM 604772]).
1 CPVT is characterized by episodic syncope and/or sudden cardiac arrest induced by exercise or acute emotion. 2, 3 The ECG is usually within normal limits at rest and often displays prominent U waves, but ventricular arrhythmias might arise at times of adrenergic activation. 4, 5 The arrhythmias, typically bidirectional and/or polymorphic VT, can develop into ventricular fibrillation and sudden death, leading to a high mortality rate (30%-50% by the age of 30) for this disorder. 6 CPVT often manifests in childhood, and a family history of juvenile sudden death and stressinduced syncope is present in approximately one-third of the cases. It can present as sudden death in children without any prior signs or warning, 6 and it has been estimated to cause up to 15% of unexplained sudden cardiac deaths in young people. 7 Previously, familial assessment revealed little evidence of the condition in many victims of unexplained sudden death. 8, 9 Mutations in the ryano- 14 Tightly controlled cycling of the intracellular calcium concentration is the basis for cardiac muscle contraction and determination of the heart rhythm. RYR2 is the sarcoplasmic reticulum (SR) calcium release channel. Upon a small increase in local intracellular Ca 2þ concentration
(from approximately 100 nM to a few micromolar), this channel switches from a closed to an open conformation, resulting in a large influx of Ca 2þ from the SR storage and ultimately causing muscle contraction. The current molecular understanding of RYR2-associated VT is that RYR2 mutations render the tetrameric RYR2 complex ''leaky,'' thereby leading to increased local Ca 2þ concentrations (Ca 2þ sparks), untimely activation of nearby RYR2 clusters through calcium-induced calcium release (CICR), and eventual arrhythmia. 15, 16 The precise molecular mechanism is, however, still unclear, and it has been put forward that an abnormal interaction with one or more of the associated proteins or ions, such as FKBP12.6 or CASQ2, or abnormal activation by extraluminal or intraluminal Ca 2þ ions also might play a role, as reviewed by Kontula et al. 16 and Mohler et al. 17 Here we report a Swedish multiplex family presenting with a history of ventricular arrhythmias, syncopes and sudden death, predominantly in association with physical exercise or stress ( Figure 1A ). The index case (II:6), a now 42-year old man of Swedish ethnic origin, presented with syncope while playing football at the age of 12. The ECG at admission ( Figure 1B , upper panel) showed sinus bradycardia (HR ¼ 45/min) and prominent U-wave in V2 and V3, but no evidence of QT prolongation (QTc ¼ 0.42 s). He had a history of loss of consciousness on at least four occasions during physical activity and once in connection with a fire alarm. A 24 hr ECG registration revealed ventricular extrasystoles (VES), bigemini, and paired Figure 1. Pedigree and Electrocardiography (A) Pedigree of Swedish family with the chromosome 14 haplotypes presented graphically with HaploPainter. 18 The index case is indicated with an arrow. The individuals included in the initial SNP genome-wide linkage analysis are marked by an asterisk. (B) The ECG during rest and an arrhythmia event (while the individual was playing football) occurring during a 24 hr ECG registration of the index case II:6 of family 1. (C) Resting and exercise ECGs from a second, unrelated individual of Iraqi origin. Both resting ECGs demonstrate prominent U waves in the anterior leads, and bidirectional ventricular ectopy is seen during physical activity or exercise. Figure 1B , lower panel) during football training, but no symptoms were reported. He was started on b1-adrenergic-receptor blocker treatment. At follow up, a 24 hr ECG and exercise test still showed some VES and bigemini under conditions of increasing load and heart rate. A genomic DNA sample from the index case was later screened for mutations in a panel of arrhythmia-associated genes, including RYR2 and CASQ2, where no mutations were identified. An older brother (II:4), aged 23, had a history of repeated syncope during exercise. During an exercise test, he displayed polymorphic VT (an ECG from that time is not available). After treatment with b1-adrenergic-receptor blocker, a follow-up exercise test showed VES at high loads. The family history also included a brother (II:3) who drowned during a swimming competition at age 15 after having had prior episodes of syncope and an older sister (II:2) who suffered from fits or syncope. After a later episode of ventricular fibrillation (VF), she was stabilized by treatment with b1-adrenergic-receptor blocker and became asymptomatic. A younger sister (II:8) presented at the age of 7 with a history of repeated syncope during intense physical activity. One younger family member (III:5), with reported syncope from age 2.5, died suddenly at age 13, having been treated with b1-adrenergic-receptor blocker for several years. Another family member (III:4) started having syncope at age 4, was asymptomatic under treatment with b1-adrenergicreceptor blocker, and suffered cardiac arrest at age 16. After rapid defibrillation and resuscitation, she recovered and had an ICD implanted. An older sister (III:2) presented with syncope from age 6-7 and became asymptomatic under treatment with b1-adrenergic-receptor blocker. A younger sister (III:6) presented with syncope at age 3-4. Family members III:9, III:12, and IV:1 were put on b1-adrenergic-receptor blocker after having suffered syncope and attacks of dizziness. According to the family, subject I:1 suffered multiple cases of syncope in her youth and was on medication. She died at 60 years old. Thus, the phenotypic picture of the family is characterized by CPVTlike features with symptoms including frequent syncope and three cases of sudden death or cardiac arrest. The affected family members display no other apparent clinical manifestations.
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All procedures were in accordance with the ethical standards of the responsible committees (institutional and national) on human experimentation. After obtaining informed consent from all the subjects, we extracted genomic DNA from peripheral blood samples from all the subjects to perform linkage analysis. Initially, 12 subjects (nine affected and three unaffected, indicated by an asterisk in Figure 1A) were genotyped with the Human Mapping 50K SNP Xba240 Array (Affymetrix, High Wycombe, UK). The unaffected subjects were all older than 16 years at the time of inclusion. Genotypes were called by the Genotyping Console (Affymetrix) and uploaded to the BCSNP data management platform (BC Platforms, Espoo, Finland) for quality-control filtering (58,958 markers). Markers with Mendelian errors were detected with MERLIN 19 and removed from the data set. Removal of monomorphic markers and LD pruning (for which a sliding window of 50 SNPs and an r 2 threshold of 0.5 was used) was performed with PLINK 20 and resulted in a filtered data set of 7,199 markers in approximate linkage equilibrium with each other. MERLIN was used for the identification of unlike genotypes, resulting in the removal of 292 genotypes from the data set. A parametric linkage analysis assuming autosomal-dominant inheritance with complete penetrance and a disease gene frequency of 0.0001 was carried out with MERLIN with allele frequencies from the Affymetrix 100K frequency files (CEU population) and genetic distances from the Affymetrix 100K Marshfield cM map. Two possible linked loci were identified (on chromosomes 14q31-32 and 6q27-qter), each with a maximum LOD score of 3.01 ( Figure S1 in the Supplemental Data available online). A follow-up analysis with microsatellite markers (D14S1037, D14S68, D14S81, D14S65, D6S305, D6S386, and D6S1590) in these two regions was performed and included an additional six subjects from the family (one affected, IV:1; two unaffected, III:10 and III:11; and three healthy married-in individuals, II:1, II:5, and II:7). In total, 18 individuals with the microsatellite markers were genotyped. Primer sequences were retrieved from the NCBI UniSTS database. The microsatellite analysis excluded the locus on chromosome 6 and mapped the disease locus to chromosome 14 (LOD score 3.9) ( Figure 2A ). A haplotype analysis confirmed the presence of the chromosome 14 disease haplotype in all affected and none of the unaffected individuals ( Figure 1A ), suggesting 100% penetrance of the mutation in this family. The peak on chromosome 14 extended approximately 21 cM, from rs9323782 (86.6Mb) to rs721403 (95.7Mb) (hg19) (Table S2 ), a region that harbors around 70 genes ( Figure S2 and Table S3 ). Because of the pivotal role of calmodulin in calcium signaling and heart contraction, CALM1 was selected for sequencing. Primers amplifying the coding regions, adjacent splice sites, and the 5 0 -and 3 0 -untranslated regions of CALM1 were designed with Primer3 24 (Table S1 ). The amplified products were purified and sequenced on both strands at MWG (Eurofins MWG Operon, Ebersberg, Germany). Sequencing one affected family member (the index case) and one unaffected family member revealed a heterozygous missense mutation c.161A>T [GenBank NM_006888.4] in exon 3. This mutation results in a change from asparagine (Asn) to isoleucine (Ile), p.Asn53Ile (UniProtKB P62158, notated without the initiator methionine residue to reflect the mature processed calmodulin) in the index case ( Figure 2B ). A genotyping assay for p.Asn53Ile for the LightCycler 480 instrument (Roche, Hvidovre, Denmark) was developed by TIB MOLBIOL (Berlin, Germany) (Table S1 ). Genotyping with LightCycler 480 Genotyping Master Mix (Roche) confirmed that the p.Asn53Ile substitution was present in all affected individuals and absent in all of the unaffected individuals in the pedigree. Genotyping of 1,200 control individuals (500 Danish medical student volunteers from Aarhus University and 700 anonymous Danish blood donors) showed that the mutation was absent among these 2,400 control chromosomes. This sample size provided an 80% power to detect a variant with a minorallele frequency of 0.001, 25 verifying that the mutation is highly unlikely to be a normal but rare sequence variation.
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To systematically screen for other mutations in CALM1, we developed a mutation-detection assay for each of the five coding exons on the basis of high-resolution melting (HRM) of amplified PCR products. All assays were carried out with 480 High Resolution Melting Master (Roche) and HPLC purified primers (MWG). Sixty-three individuals, referred for RYR2 mutation analysis at the Statens Serum Institute in Denmark (where genetic testing failed to identify any RYR2 mutation in 61 of these individuals), were analyzed in duplicate. All samples with aberrant melting curves, as well as ten control samples with normal melting curves, were sequenced (primer sequences are listed in Table S1 ). From this screening a second heterozygous CALM1 missense mutation was identified in an individual of Iraqi origin. The mutation (c.293A>G) was located in exon 5 and resulted in an asparagine-to-serine substitution (p.Asn97Ser) ( Figure 2B ). DNA sequencing revealed that this mutation was absent in the mother and the father, neither of whom showed signs of heart arrhythmias, demonstrating the presence of a de novo mutation in this individual. A microsatellite marker analysis confirmed the paternity relationship. The individual with the de novo CALM1 mutation was a 23-year-old female who presented at age 4 with a successfully resuscitated, out-ofhospital cardiac arrest due to VF while she was running. She made a full neurological recovery and was stabilized by treatment with b1-adrenergic-receptor blocker. An initial ECG and echocardiogram were within normal limits, and there was no evidence of QT prolongation (not shown). Evaluation of her immediate family was unremarkable. An exercise ECG and electrophysiological study undertaken on full betablockade and right ventricular and coronary angiography were within normal limits. An initial diagnosis of idiopathic VF was made at the time. Follow-up ECGs demonstrated prominent U waves in the anterior leads but no evidence of the long-QT or Brugada syndromes ( Figure 1C Figure 1C, lower panel) . These appeared to be bidirectional at times. On this basis, a diagnosis of CPVT was made, but genetic testing of RYR2, CASQ2, and KCNJ2 failed to identify any mutations in these genes. In a follow-up genetic test of other arrhythmia-associated genes, including KCNQ1 (MIM 607542), KCNH2 (MIM 152427), KCNE1 (MIM 176261), KCNE2 (MIM 603796), and SCN5A (MIM 600163), no mutations were found. She fainted twice more in her teens, and at age 15 she suffered a further cardiac arrest. After recovery, an ICD was implanted, and she remained well but was diagnosed with systemic lupus erythematosus (SLE [MIM 152700]). Her mother, aged 62, was asymptomatic until developing heart failure secondary to adriamycin-induced cardiomyopathy from breast cancer treatment. She did not experience syncope or arrhythmia. An ECG demonstrated left-bundle-branch block and leftward axis deviation. Her father, aged 66, had suffered nonexertional syncope in stressful situations, consistent with vasovagal syncope. His resting ECG was normal, and exercise testing for atypical chest pain had induced ischemic changes without arrhythmia. An angiogram was reported as showing unobstructed coronaries and vasospasm.
Both CALM1 mutations thus appear to induce an earlyonset and highly penetrant phenotype that belongs to the severe end of the spectrum of CPVT-like arrhythmias. In accordance with this, an initial response to therapy with b1-adrenergic-receptor blocker was observed with subsequent recurrent symptoms both in the Iraqi case and in individuals III:4 and III:5 in family 1. The fact that p.Asn97Ser is a de novo substitution is fits well with the presentation of the associated disease as a highly malignant form with very early presentation and is consistent with the RYR2-associated disease, which is commonly caused by de novo mutations. 26 To assess whether CALM1 missense mutations exist in the general population, a systematic HRM screen of all five CALM1 coding exons were performed in 500 Danish control individuals. No missense mutations were (C) Alignment of calmodulin amino acid sequences from different species; the p.Asn53Ile and p.Asn97Ser substitutions are indicated (red residues). Secondary-structure elements are shown in green and orange (a-helix and b strand, respectively), and the Ca identified among these 1,000 control chromosomes. In contrast, three rare silent polymorphisms were identified (these were present among five control individuals) (Table  S4) , stressing the selection pressure against missense mutations in this gene. A specific Iraqi control population was not investigated because the mutation was de novo, and the mutation rate is likely to be the same in all populations. No missense mutations in CALM1 (ENST00000356978) were found from the 1000 Genomes Project (October 2011 release) interrogated through the Project Browser #ICHG2011 (Ensembl release 63 representing an integrated set of variant calls and INDELS from lowcoverage and exome sequencing data of 1,092 individuals). A literature search also failed to present evidence for any previously identified calmodulin mutations. The lack of identified missense mutations is not surprising given that calmodulin is known as one of the most conserved molecules throughout evolution, displays an identifical protein sequence in all vertebrate species, and has evolved only slightly since the divergence from plants ( Figure 2C ). The presence of three independent genes in the human genome (CALM1-3 [MIM 114180, 114182 and 114183]), all encoding ubiquitously expressed identical calmodulin protein molecules, further underscores the selection pressure against any amino acid changes in this classic calcium-binding protein.
Calmodulin is a 148 amino acid a-helical protein containing four classical Ca 2þ -binding EF hands that bind one calcium ion each. It is shaped as a dumbbell and is capable of mediating a signal consisting of small intracellular Ca 2þ -concentration changes to a multitude of intracellular targets via fine-tuned differences in the N-and C-domain affinity for Ca 2þ . 27 The N domain contains the loweraffinity Ca 2þ -binding sites I and II, and the C domain contains the high-affinity binding sites III and IV. The two identified substituted residues are located in opposite domains; the Asn53 residue is positioned on the solventexposed surface of the first a-helix of Ca 2þ -binding site II in the N domain, and the Asn97 residue is one of the Ca 2þ -binding residues of binding site III, located in the calmodulin C domain ( Figure 2D ). Calmodulin binds to and regulates the activity of a large number of intracellular proteins, but in none of the published high-resolution calmodulin structures available are the two substituted residues in direct contact with any bound protein or peptide, exemplified by the calmodulin-RYR1 peptide complex in Figure 2D .
To functionally characterize the substitutions, we used a nested priming approach to amplify the CALM1 cDNA (primers are listed in Table S1 ) from a cDNA preparation from liver mRNA, 28 and we ligated this cDNA into a modified pMAL vector (New England Biolabs, Ipswich, USA) containing a Tobacco Etch Virus (TEV) protease cleavage site. Missense mutations were introduced with QuickChange Lightning (QIAGEN) (primer sequences are listed in Table S1 ). The calmodulin variants were expressed in Rosetta B cells (EMD Chemicals). All buffers and reagents were prepared with purified and deionized (>18.2 U resistance) water and plastic vessels, and all laboratory equipment was washed in 1 M HCl and purified water so that Ca 2þ contamination would be minimized. The total Ca Hence, we show that both variants lead to altered calcium binding property of calmodulin and that the substituted residues impose different effects on the distribution of bound Ca 2þ between the N and C domains of calmodulin.
Next, the interaction between the calmodulin variants and a peptide from RYR2 encompassing the calmodulin binding domain (CBD), RYR2-CBD (R3581-SKKAVWH KLLSKQRKRAVVACFRMAPLYN-L3611 [Genscript, USA]), was investigated. In the high-resolution 3D structure of calmodulin bound to the equivalent peptide from RYR1, the Ca 2þ -bound C domain of calmodulin fully encloses the single tryptophan (Trp) residue of the RYR peptide (RYR1 Trp3620, corresponding to RYR2 Trp3586, Figure 2D ). Calcium binding to calmodulin leads to an N-terminal shift in its binding site on the RYR2-CBD peptide. This shift is evidenced by a large increase in fluorescence intensity of the RYR2 interaction, exerts a dominant-negative effect on the RYR2 channel complex and leads to ''inappropriate RYR2 leakiness'' similar to what is proposed for RYR2 mutations. This would also explain how one mutated calmodulin allele out of six encoding identical proteins is sufficient to cause a dominantly inherited phenotype.
Interestingly, several animal studies have recently suggested that a disturbed calmodulin RYR2 interaction plays a key role in arrhythmia and heart failure. [33] [34] [35] For example, in a study using knock-in mice harboring the human RYR2 CPVT-type substitution p.Arg2474Ser, previously found to be a model for CPVT 36, 37 Xu and co-workers investigated the RYR2-calmodulin interaction and found a markedly reduced affinity for calmodulin in response to PKA phosphorylation, which led the authors to conclude that a defective interaction between RYR2 and calmodulin is part of the pathogenic mechanism for CPVT. 35 Our results are the first human data to strongly support the molecular disease model in which an aberrant calmodulin-RYR2 interaction is causative of CPVT-like arrhythmias. The p.Asn53Ile substitution did not demonstrate a significantly compromised RYR2 interaction in the experimental setup used here. One limitation of our work is that we studied the calmodulin-RYR2 interaction by using a small peptide fragment (RYR2-CBD) instead of the large RYR2 molecular complex. Thus, it is at present unclear whether the p.Asn53Ile substitution affects the function of RYR2 in vivo. Intriguingly, the Ca 2þ -binding property of p.Asn53Ile was markedly different from the native and p.Asn97Ser calmodulin, and it is possible that a different molecular pathogenic mechanism is in play in family 1. This could be reminiscent of the mechanism suggested for ANKB mutations in CPVT given that calmodulin regulates, and AnkB is required for correct assembly of, a number of ion channels and pumps involved in cardiomyocyte contraction. For example, such ion channels and pumps include the L-type calcium channel, Na þ /K þ ATPase, Na þ /Ca 2þ exchanger, and the InsP(3) receptor. 12 In the screened clinical sample, which included 63 individuals who had unspecified arrhythmias or sudden cardiac death and had been referred for RYR2 screening, only two CALM1 mutations were detected (both the family 1 index case and the Iraqi case were included in this sample). Thus, the frequency of CALM1 mutations is seemingly low from this finding. However, because only two individuals were found to be positive for RYR2 mutations, the frequencies of CALM1 and RYR2 mutations were identical in this sparsely characterized and heterogeneous sample collection. More accurately establishing the frequency and phenotypic variation of CALM1 mutations in CPVT and related disorders will require screening of large well-characterized clinical samples. Before this is done, we cannot exclude that CALM1 is a rare contributor to CPVT.
In conclusion, we have identified two functionally distinct CALM1 missense mutations that lead to development of early-onset CPVT or CPVT-like arrhythmia. Our finding will directly allow presymptomatic genetic diagnosis in families in which members with this severe disorder harbor CALM1 mutations, enabling the initiation of potentially life-saving treatment for children and young individuals with disease mutations. As a consequence of our findings, the three calmodulin genes are candidates for genetic screening of individuals with CPVT-like arrhythmia and unexplained sudden cardiac death.
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